In wake of PhII flop, Roche walks away from $350M Covid-19 an­tivi­ral pact

A month af­ter con­ced­ing a mid-stage fail­ure, Roche is drop­ping the Covid-19 an­tivi­ral pill it was joint­ly de­vel­op­ing with Atea.

The lit­tle biotech, which had …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER